Correction to: Nature Medicine https://doi.org/10.1038/s41591-022-02182-7. Published online 23 January 2023.
In the version of this article initially published, the clinical trials registration number NCT04093596 was missing from the Abstract and has now been amended in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mailankody, S., Matous, J.V., Chhabra, S. et al. Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 29, 3271 (2023). https://doi.org/10.1038/s41591-023-02306-7
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-023-02306-7
This article is cited by
-
Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
Molecular Biology Reports (2026)
-
Recent updates on allogeneic CAR-T cells in hematological malignancies
Cancer Cell International (2024)
